MAPT and Cognitive impairment: In summary, in this large heterogeneous sample of patients with cognitive impairment referred to secondary memory clinics, our results indicate that classifying patients based on the presence of LB, Aβ and tau pathologies identifies subgroups with distinct clinical phenotypes and trajectories that are not captured by using clinical syndromes or classification according to the standard Aβ and tau biomarkers.